Literature DB >> 9058291

Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori.

P Moayyedi1, D M Chalmers, A T Axon.   

Abstract

Omeprazole (20 mg od/b.d.), clarithromycin (250 mg b.d.) and tinidazole (500 mg b.d. for 7 days) [OCT] is an effective regimen against Helicobacter pylori. However, treatment fails in 5%-10% of patients and the reasons for this are not clear. We investigated patient factors that independently predicted failure of this regimen. H. pylori-positive patients were prescribed OCT and the success of treatment was evaluated by the 13C-urea breath test at least 4 weeks after completion of therapy. Patients were prospectively interviewed on past medical history of peptic ulcer and H2-receptor antagonist (H2RA) pre-treatment, smoking history, and alcohol intake. Data were also collected on age, gender, and endoscopic diagnosis to determine factors predicting failure of OCT. H. pylori eradication was achieved in 238 of 273 patients [87%-95% confidence intervals (CI), 83%-91%]. Age, alcohol intake, past medical history of peptic ulcer and peptic ulcer at endoscopy were not independently associated with treatment failure. H. pylori eradication with OCT was less successful in women (P = 0.02), in patients who had received H2RA pre-treatment (P = 0.02), and in smokers (P = 0.02) when evaluated by multiple logistic regression. These findings indicate that OCT is less effective in smokers and in patients who receive H2RA pre-treatment suggesting that these agents should be avoided, if possible, before the patient commences therapy. H. pylori eradication was less successful in women; this result needs further evaluation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9058291     DOI: 10.1007/bf01213292

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  19 in total

1.  Twenty-four hour intragastric acidity and plasma gastrin concentration profiles in female and male subjects.

Authors:  E J Prewett; J T Smith; C U Nwokolo; A M Sawyerr; R E Pounder
Journal:  Clin Sci (Lond)       Date:  1991-06       Impact factor: 6.124

2.  One week eradication regimen for Helicobacter pylori.

Authors:  R P Logan; P A Gummett; J J Misiewicz; Q N Karim; M M Walker; J H Baron
Journal:  Lancet       Date:  1991-11-16       Impact factor: 79.321

3.  One-week low-dose triple therapy: new standards for Helicobacter pylori treatment.

Authors:  A Goddard; R Logan
Journal:  Eur J Gastroenterol Hepatol       Date:  1995-01       Impact factor: 2.566

Review 4.  The role of acid inhibition in the treatment of Helicobacter pylori infection.

Authors:  A T Axon
Journal:  Scand J Gastroenterol Suppl       Date:  1994

5.  Medium-term results of oral and intravenous omeprazole/amoxicillin Helicobacter pylori eradication therapy.

Authors:  R J Adamek; M Wegener; J Labenz; M Freitag; W Opferkuch; G H Rühl
Journal:  Am J Gastroenterol       Date:  1994-01       Impact factor: 10.864

6.  Effects of omeprazole on gastric mucosal microcirculation and acid secretion in the rat.

Authors:  L Holm-Rutili
Journal:  Gastroenterology       Date:  1987-03       Impact factor: 22.682

7.  Intravenous indomethacin and aspirin reduce basal gastric mucosal blood flow in dogs.

Authors:  G L Kauffman; D Aures; M I Grossman
Journal:  Am J Physiol       Date:  1980-02

8.  Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori.

Authors:  P Moayyedi; P Sahay; D S Tompkins; A T Axon
Journal:  Eur J Gastroenterol Hepatol       Date:  1995-09       Impact factor: 2.566

9.  Experience with 'triple' anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance.

Authors:  G D Bell; K Powell; S M Burridge; A Pallecaros; P H Jones; P W Gant; G Harrison; J E Trowell
Journal:  Aliment Pharmacol Ther       Date:  1992-08       Impact factor: 8.171

10.  Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success.

Authors:  J Labenz; F Leverkus; G Börsch
Journal:  Scand J Gastroenterol       Date:  1994-12       Impact factor: 2.423

View more
  18 in total

1.  13C-urea breath test for success of Helicobacter pylori eradication: study of 5885 Israeli patients.

Authors:  Y Niv; R Koren
Journal:  Dig Dis Sci       Date:  2005-08       Impact factor: 3.199

2.  Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment success in 7-day treatment regimen for cure of H. pylori infection: a multiple logistic regression analysis.

Authors:  H Miwa; H Misawa; T Yamada; A Nagahara; K Ohtaka; N Sato
Journal:  Dig Dis Sci       Date:  2001-11       Impact factor: 3.199

3.  One-year follow-up study of Helicobacter pylori eradication rate with 13C-urea breath test after 3-d and 7-d rabeprazole-based triple therapy.

Authors:  Hwang-Huei Wang; Jen-Wei Chou; Kuan-Fu Liao; Zong-Yi Lin; Hsueh-Chou Lai; Chang-Hu Hsu; Chih-Bin Chen
Journal:  World J Gastroenterol       Date:  2005-03-21       Impact factor: 5.742

Review 4.  A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy.

Authors:  U Peitz; A Hackelsberger; P Malfertheiner
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

5.  13C-urea breath test for diagnosis of Helicobacter pylori infection in the elderly.

Authors:  Yaron Niv; Galia Niv; Rivka Koren
Journal:  Dig Dis Sci       Date:  2004 Nov-Dec       Impact factor: 3.199

Review 6.  Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.

Authors:  H D Langtry; M I Wilde
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

7.  Effect of smoking on failure of H. pylori therapy and gastric histology in a high gastric cancer risk area of Colombia.

Authors:  M Constanza Camargo; M Blanca Piazuelo; Robertino M Mera; Elizabeth T H Fontham; Alberto G Delgado; M Clara Yepez; Cristina Ceron; Luis E Bravo; Juan C Bravo; Pelayo Correa
Journal:  Acta Gastroenterol Latinoam       Date:  2007-12

8.  Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication.

Authors:  Young Woon Chang; Ga Young Shin; Jung-Wook Kim; Jin-Chang Moon; Eun Jee Chang; Chi Hyuk Oh; Jae-Young Jang
Journal:  Dig Dis Sci       Date:  2021-03-23       Impact factor: 3.199

9.  Online Registry for Nationwide Database of Current Trend of Helicobacter pylori Eradication in Korea: Interim Analysis.

Authors:  Beom Jin Kim; Hyun-Soo Kim; Hyun Joo Song; Il-Kwun Chung; Gwang Ha Kim; Byung-Wook Kim; Ki-Nam Shim; Seong Woo Jeon; Yun Jin Jung; Chang-Hun Yang; Ji Hyun Kim; Tae Ho Kim; Sang Gyun Kim; Woon Geon Shin; Sun Moon Kim; Sok Won Han; Jun Haeng Lee; Kyung Ho Kim; Sue K Park; Byung-Joo Park; Joongyub Lee; Jae G Kim
Journal:  J Korean Med Sci       Date:  2016-05-16       Impact factor: 2.153

10.  Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy.

Authors:  Sung Eun Kim; Moo In Park; Seun Ja Park; Won Moon; Youn Jung Choi; Ji Hyun Cheon; Hye Jung Kwon; Ki Hwan Ku; Chang Hun Yoo; Jae Hyun Kim; Gyu Won Lee; Sung Eun Song
Journal:  Korean J Intern Med       Date:  2015-10-30       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.